Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer (Q60156355)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164156%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164156%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164156%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Philip W. Kantoff

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164156%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

author name string

D J George

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164156%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

K Hackmann

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164156%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

J Manola

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164156%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

language of work or name

English

0 references

publication date

1 January 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164156%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164156%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164156%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164156%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

122-126

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164156%20AND%20SRC:MED&resulttype=core&format=json

Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900986-9

7 January 2021

Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900986-9

7 January 2021

PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo .

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900986-9

7 January 2021

Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900986-9

7 January 2021

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900986-9

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900986-9

7 January 2021

Individual Comparisons by Ranking Methods

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900986-9

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900986-9

7 January 2021

PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900986-9

7 January 2021

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900986-9

7 January 2021

Low-dose continuous oral fosfestrol is highly active in 'hormone-refractory' prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900986-9

7 January 2021

Mechanisms of action and clinical uses of estramustine

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900986-9

7 January 2021

10.1016/S0090-4295(00)00986-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11164156%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference